Quick Answer
There is no single yes or no answer to "are peptides legal," because "peptides" describes a chemical shape, not a legal status. A drug store GLP-1 injection, a compounding pharmacy's prescription, and a vial labeled "research use only" can all contain a peptide, and each one sits in a completely different part of federal drug law. The table below is the short version. The rest of this guide walks through each category in plain language.
| Category | Current status (September 2026) |
|---|---|
| FDA-approved peptide drugs | Legally available by prescription, went through full FDA clinical review. Examples: semaglutide, tirzepatide. |
| Compounded peptides under Section 503A | Not yet legal for BPC-157, TB-500, MOTS-c, and similar research peptides. None are on the FDA's 503A Bulks List yet. |
| Research chemicals ("not for human consumption") | How most commonly discussed research peptides are currently sold. Not reviewed by the FDA for safety or efficacy. |
| Import, customs, and state rules | Varies and can change. General information only, not something to rely on for a specific decision. |
Why "Peptides" Isn't One Legal Category
It helps to stop thinking of "peptide" as a legal term at all. It's a chemistry term, describing a short chain of amino acids. Insulin is a peptide. Semaglutide is a peptide. BPC-157 is a peptide. Those three have wildly different legal statuses, because what determines legality isn't the molecule itself, it's how that specific substance has moved, or hasn't moved, through the FDA's regulatory pathways.
Broadly, a peptide discussed on a site like this one falls into one of four buckets: an FDA-approved drug available by prescription, a substance a compounding pharmacy could legally prepare under Section 503A, a research chemical sold without a drug claim, or a substance whose status is additionally shaped by import and state-level rules. Each is covered in its own section below.
1. FDA-Approved Peptide Drugs
This is the only category where the legal picture is genuinely simple. An FDA-approved peptide drug has gone through the FDA's full clinical trial process, meaning studies on safety and effectiveness were reviewed and the agency signed off on a specific formulation, dose, and indication. These are available legally by prescription through a licensed pharmacy.
The clearest current examples are semaglutide and tirzepatide, both FDA-approved GLP-1 receptor agonist drugs used for weight management and type 2 diabetes, sold under brand names most people recognize. See our full semaglutide vs. tirzepatide comparison for how the two approved drugs differ.
The sermorelin history worth knowing
Sermorelin has an interesting regulatory past that gets conflated with its present. It was once FDA-approved under the brand name Geref for pediatric growth hormone deficiency. That approved product was later discontinued commercially, and importantly, that discontinuation was a business decision, not a safety withdrawal. That history does not carry over to the sermorelin sold today as a research chemical. A product being sold under that name now does not have the same regulatory status as the discontinued, once-approved Geref formulation. See FDA-Approved Peptides vs. Research Peptides for more on how these two categories get confused.
2. Compounded Peptides Under Section 503A
Section 503A of the Federal Food, Drug, and Cosmetic Act lets a licensed pharmacy legally compound a substance for an individual patient's prescription, but only under specific conditions. The substance has to meet at least one of three requirements: it's on the FDA's Section 503A Bulk Drug Substances List, it has its own U.S. Pharmacopoeia or National Formulary (USP/NF) monograph, or it's a component of an already FDA-approved drug.
As of today, September 2026, none of the commonly discussed research peptides, including BPC-157, TB-500, MOTS-c, KPV, Semax, Epitalon, CJC-1295, Ipamorelin, Selank, and DSIP, are on that Bulk Drug Substances List. That means, right now, a compounding pharmacy cannot legally prepare any of these as a patient-specific prescription under Section 503A.
What did change in 2026: on July 23 to 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding six of seven reviewed peptides, BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon, to the 503A Bulks List. DSIP, reviewed under the name Emideltide, was the one substance the committee did not recommend.
That vote is a real development, but it's easy to overstate what it means. A PCAC recommendation is nonbinding. The FDA is not required to act on it, and as of this writing, the FDA has not adopted it. For any of these peptides to actually become legally compoundable under Section 503A, the FDA would need to complete a formal notice-and-comment rulemaking process, which includes a proposed rule and a public comment period before a final rule takes effect, or Congress would need to amend the underlying statute. Neither of those has happened. For the full story on that vote, including how the committee split and what happens next, see What Changed With BPC-157, TB-500 and MOTS-c in 2026. For the current status of every individual compound, updated as things change, see the FDA Peptide Status Tracker. For a deeper explanation of what "compounded" actually means and how it differs from a manufactured drug, see What Is a Compounded Peptide?.
3. Research Chemicals Sold "Not for Human Consumption"
This is how most of the peptides discussed on BioStackIQ, including BPC-157, TB-500, MOTS-c, CJC-1295, Ipamorelin, Selank, Semax, Epithalon, KPV, and DSIP, are currently sold: as research chemicals labeled "research use only" or "not for human consumption."
In plain terms, that labeling generally means the seller isn't making a drug claim about the product, and the product hasn't gone through FDA review for human safety or efficacy. It's a way of selling a compound outside the drug approval framework entirely, rather than a claim that the product has been evaluated and found safe.
What that labeling does not automatically mean is that possessing the substance itself is illegal. That said, this is genuinely where general information has to stop and individual legal judgment has to start. How a product is marketed, what claims are made about it, and how it's actually used can raise separate legal questions from the labeling alone, and those questions depend on specifics this article can't evaluate for you. We're not able to give a definitive answer about what any individual reader may or may not legally do, and this section should be read as general information only, not legal advice. If this matters for your situation, get your own legal counsel. For more on what the "research use only" label does and doesn't mean, see What Does "Research Use Only" Actually Mean?.
4. Import, Customs, and State-Level Variation
There's one more layer worth flagging briefly: how a peptide shipment is treated at customs, and how individual states approach these substances, can both vary and can change over time. This is a genuinely complex, moving area, and it's not something a single article can map out completely or keep current on its own. If import or state-specific rules matter for your situation, treat this section as a pointer to go look into it further, not as a complete answer.
How to Think About This as a BioStackIQ User
Put together, the picture looks like this: a small number of peptides, like semaglutide and tirzepatide, are FDA-approved prescription drugs. A larger group, including the peptides most often discussed for research purposes, are not yet legally compoundable under Section 503A, even after the FDA's 2026 advisory committee vote recommended a path toward that. Most of what's actually sold and discussed today falls into the research chemical category, sold without a drug claim and without FDA safety review. And on top of all of that, import and state-level rules add a layer of variation this article can only flag, not fully resolve.
None of this changes based on which tools you use to track a protocol. BioStackIQ's Rate My Stack and Peptide Protocol Builder are built to help you organize and evaluate a protocol you've already decided to pursue, they aren't a substitute for understanding the legal category a given substance sits in, or for your own legal and medical judgment about it.
Related Reading
For a closer look at how FDA-approved drugs differ from research peptides in general, see FDA-Approved Peptides vs. Research Peptides. To understand exactly what a "research use only" label does and doesn't mean, see What Does "Research Use Only" Mean?. For how the Section 503A compounding pathway actually works, see What Is a Compounded Peptide?. For the full story behind the FDA's July 2026 committee vote, see What Changed With BPC-157, TB-500 and MOTS-c in 2026, and for the live, per-compound regulatory picture, see the FDA Peptide Status Tracker. For the two FDA-approved GLP-1 drugs specifically, see Semaglutide vs. Tirzepatide.